Suven Life Sciences is currently trading at Rs. 312.80, up by 6.30 points or 2.06% from its previous closing of Rs. 306.50 on the BSE.
The scrip opened at Rs. 309.00 and has touched a high and low of Rs. 319.00 and Rs. 307.80 respectively. So far 207909 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 337.70 on 11-Sep-2018 and a 52 week low of Rs. 162.50 on 13-Sep-2017.
Last one week high and low of the scrip stood at Rs. 337.70 and Rs. 276.20 respectively. The current market cap of the company is Rs. 3964.85 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 6.69% and 33.31% respectively.
Suven Life Sciences has secured one product patent from New Zealand and one product patent from Sri Lanka corresponding to the New Chemical Entity for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2034 and 2031 respectively.
The granted claims of the patents include the class of selective 5-HT4 and H3 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia and sleep disorders like Narcolepsy etc.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: